Health Care

S.391 and H.R. 475 update the existing excise tax to cover newly approved season flu vaccines

At the 2013 BIO International Convention, Mundel discusses biotech start-ups and how biotech and technology can help meet needs in developing countries. The Global Burden of Disease Study 2010 (GBD 2010) is the largest ever systematic effort to describe the global distribution and causes of a wide array of major diseases, injuries, and health risk factors. The results show that infectious diseases, maternal and child illness, and malnutrition now cause fewer deaths and less illness than they did twenty years ago.

Dr. Richard Mohs, Distinguished Research Fellow, Eli Lilly discusses the importance of early diagnosis in Alzheimer's at the 2013 BIO International Convention.

Kathleen Ruddy, CEO of the St. Baldricks Foundation, the world's largest funder of childhood cancer research grants outside of the federal government explains the type of relationships they hope to develop at the 2013 BIO International Convention.

Keynote speaker Josh Sommer was recently named one of Forbes 30 Under 30 in Life Sciences and Healthcare. He discusses his rare cancer diagnosis while in college and his subsequent journey to become the Executive Director of The Chordoma Foundation. He also explains his search for information, insight and connections at the BIO International Convention.

Seth Ginsberg, President of the Global Healthy Living Foundation discusess their healthy biologics initiative to improve the quality of life for people with chronic illnesses at the 2013 BIO International Convention.

From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013.

Congress created the 340B program in 1992 to help uninsured indigent patients gain better access to prescription medicines. This white paper examines the history and original intent of the program as well as highlights key findings to help policymakers ensure that the 340B program meets its stated purpose and to provide a roadmap for next steps to be considered.

The biosimilars pathway is critical for China's biotechnology industry – and this is evident in the investment the government is making in the manufacture of biotech products

In the next several months, the president and members of Congress will decide whether to continue the funding and authorities associated with Project BioShield, which seeks to expand the U.S. stockpile of medical countermeasures for potential chemical, biological, radiological and nuclear (CBRN) attacks.

Biotechnology companies must have some certainty that they can protect their investment in the development of new breakthrough therapies for a substantial period of time.

In an effort to bring innovative new medicines to patients more efficiently, while protecting and enhancing patient safety, BIO is developing an initiative to modernize clinical trials.

William Schaffner, MD, the immediate past president of the National Foundation for Infectious Diseases, explains why it is important for all adults to become fully immunized according to recommended schedules.

Successful multi-sector global health programs engage partners and policymakers early, communicate openly and frequently with relevant stakeholders, and empower and involve communities, according to a website relaunched this week, Case Studies for Global Health.

Letters, Testimony & Comments

May 8 2013
  Dear Sir/Madam:   The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for...
May 7 2013
Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
April 19 2013
  The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the “WHO Guidelines on the Quality...
April 12 2013
Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
April 8 2013
BIO supports the goals of the Affordable Care Act (ACA) in providing greater transparency regarding financial relationships with...

Press Releases

February 28 2013
WASHINGTON, DC – February 28, 2013 –The Biotechnology Industry Organization (BIO) lauds the Senate for...
January 25 2013
The Biotechnology Industry Organization lauds the House of Representatives for passing H.R. 307, the Pandemic and All...
October 1 2012
Washington, D.C. (October 1, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and...
July 23 2012
Groups Issue Booklet to Help Biotechnology and Pharmaceutical Companies Identify Pipeline Medicines with Doping...
June 28 2012
  Pleased to move forward on biosimilars pathway Washington, D.C. (June 28, 2012) –Biotechnology...